MRNA - Moderna's Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial | Benzinga
Tuesday, Moderna Inc (NASDAQ:MRNA) said that mRNA-1283, the company’s next-generation COVID-19 vaccine, has met the primary endpoints of its Phase 3 trial.
The data demonstrated a higher immune response against SARS-CoV-2 than mRNA-1273.222, Moderna’s licensed COVID-19 vaccine.
“We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform,” said Stéphane Bancel, Chief Executive Officer of Moderna. “mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much ...